Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Piotr Koralewski"'
Autor:
Stefano Stabile, Constantin Volovat, Piotr Koralewski, Krassimir Koynov, Iulian Bobe, Adina Croitoru, Juneko E. Grilley Olson, Tudor-Eliade Ciuleanu, Giulio Cerea, Atsushi Osada, Simona Ruxandra Volovat
Publikováno v:
Oncotarget
NC-6004 is a nanoparticle developed using micellar technology that can improve release of cisplatin, a standard treatment for many cancer types, and achieve selective distribution to tumors. Here, in the Phase II portion of this study, the activity,
Autor:
Boris Kasparov, Philip Clingan, Natalia Fadeeva, Andrey Akopov, Margaret McGrath, Vasiliy Oschepkov, Vadim Kozlov, Arunee Dechaphunkul, Virote Sriuranpong, James Oliviero, D. Harris, Fedor Moiseenko, Andrea Tazbirkova, Piotr Koralewski, Chaiyut Charoentumn, Iwona Lugowska, Nadezhda Kovalenko, Dariusz Kowalski, Daniel Brungs, Andrew Mant, Rahul Ladwah
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Cosibelimab is a high affinity, fully-human IgG1 monoclonal antibody that directly binds to programmed death ligand-1 (PD-L1) and blocks its interaction with the programmed death receptor-1 (PD-1) and B7.1 receptors to restore an anti-tumo
Autor:
Francis Parnis, Jae-Lyun Lee, Kaisa Sunela, Cristiane Decat Bergerot, Janice Pan, Hilary Glen, Karen O'Hara, Sumanta K. Pal, Sun Young Rha, Javier Puente, Lee Bennett, Piotr Koralewski, Jinyi Wang, Tudor Ciuleanu, Daniel Castellano, Daniil Stroyakovskiy, Boris Alekseev, Daniel Y.C. Heng
Publikováno v:
Journal of Clinical Oncology. 39:314-314
314 Background: Renal cell carcinoma (RCC) is the most common type of kidney cancer, constituting 80% to 85% of primary renal neoplasms. Preserving health-related quality of life (HRQOL) is an important goal during RCC treatment, but HRQOL analyses i
Autor:
Tudor Ciuleanu, Terri A. Binder, Karen O'Hara, Hilary Glen, Lixian Peng, Daniel Y.C. Heng, Boris Alekseev, Daniil Stroyakovskiy, Daniel Castellano, Alan D. Smith, Piotr Koralewski, Francis Parnis, Jae-Lyun Lee, Kaisa Sunela, Sumanta K. Pal, Sun Young Rha, Javier Puente
Publikováno v:
Journal of Clinical Oncology. 39:307-307
307 Background: LEN 18 mg + EVE 5 mg is approved for advanced RCC following anti-angiogenic therapy. Study 218 was a phase II study evaluating LEN 14 mg vs LEN 18 mg, both in combination with EVE 5 mg, for the treatment of clear cell RCC following tr
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney
Autor:
Cezary Szczylik, Mayer Fishman, Yu Nien Sun, Andrzej Deptała, Piotr Koralewski, Karolyn Kracht, Bernard Escudier, Rodryg Ramlau, Brian I. Rini, Michael Bass, Luc Dirix, Alain Ravaud, Wojciech Rogowski, Markus Puhlmann, Nizar M. Tannir, Piotr Tomczak
Publikováno v:
Cancer. 118:6152-6161
Upregulation of proangiogenic factors in response to inactivation of the von Hippel-Lindau (VHL) gene is a critical component in the development and progression of clear cell renal cell carcinoma (RCC).1 Several inhibitors of the vascular endothelial
Autor:
Didier Debieuvre, Jean-Marc Limacher, Elisabeth Quoix, A. Madroszyk, Marc Buyse, Jean-Yves Bonnefoy, Z. Papai, Erich Stoelben, Gisèle Lacoste, Piotr Koralewski, Hervé Lena, Denis Braun, Alain Rivière, Marie-Pierre Chenard, Bérangère Bastien, Jean-Luc Breton, Annette Tavernaro, Rodryg Ramlau, Bruce Acres, Nadine Bizouarne, Virginie Westeel
Publikováno v:
Lancet Oncology
Lancet Oncology, Elsevier, 2011, 12 (12), pp.1125-1133. 〈10.1016/S1470-2045(11)70259-5〉
Lancet Oncology, Elsevier, 2011, 12 (12), pp.1125-1133. ⟨10.1016/S1470-2045(11)70259-5⟩
Lancet Oncology, Elsevier, 2011, 12 (12), pp.1125-1133. 〈10.1016/S1470-2045(11)70259-5〉
Lancet Oncology, Elsevier, 2011, 12 (12), pp.1125-1133. ⟨10.1016/S1470-2045(11)70259-5⟩
International audience; BACKGROUND: Chemotherapy is the standard of care for advanced stages of non-small-cell lung cancer (NSCLC). TG4010 is a targeted immunotherapy based on a poxvirus (modified vaccinia virus Ankara) that codes for MUC1 tumour-ass
Autor:
Heinz Ludwig, Anja H. Loos, A. Makhson, Carsten Bokemeyer, Gunter Schuch, Christopher Stroh, Serban Donea, A. Zubel, Joerg T. Hartmann, Igor Bondarenko, Jorge Aparicio, Filippo de Braud, Piotr Koralewski
Publikováno v:
Journal of Clinical Oncology. 27:663-671
Purpose This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorect
Autor:
Jean-Christophe Pouget, Maud Brandely, Piotr Koralewski, Mario Campone, Anna Tekiela, Isabelle Douville, Maria Blasinska-Morawiec
Publikováno v:
Cancer Chemotherapy and Pharmacology. 63:937-943
Combination of intravenous (i.v.) vinorelbine and docetaxel was shown to be feasible and effective in metastatic breast cancer (MBC). In an effort to improve patient convenience, we investigated in first-line treatment a regimen alternating i.v. and
Autor:
Alain Ravaud, Istvan Bodrogi, Agnieszka Jagiełło-Gruszfeld, Sergio Bracarda, Piotr Koralewski, Bernard Escudier, Bohuslav Melichar, Vera Gorbunova, Christine Chevreau, Marek Filipek, Anna Pluzanska, Cezary Szczylik, Emilio Bajetta, Jacques-Olivier Bay, Nicola Moore
Publikováno v:
The Lancet. 370:2103-2111
Summary Background Vascular endothelial growth factor (VEGF) inhibition is a valid therapeutic approach in renal cell carcinoma. Therefore, an investigation of the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with
Autor:
Christian Manegold, Jean-Yves Douillard, Patrick Peterson, Egbert F. Smit, William J. John, David R. Gandara, Coleman K. Obasaju, Luis Paz-Ares, Piotr Koralewski, Gee-Chen Chang, Michael Lahn, Jose Reyes
Publikováno v:
Journal of Clinical Oncology. 24:1428-1434
Purpose To determine whether aprinocarsen, an antisense oligonucleotide directed against protein kinase C-alpha, when added to the chemotherapy regimen of gemcitabine and cisplatin improved survival in patients with advanced non–small-cell lung can